The clinical trial NCT04519879, started in 2021, is a phase 2 study that aims to investigate the effectiveness of white mushroom (Agaricus bisporus) supplements in reducing PSA levels in patients with recurrent or favourable-risk prostate cancer without previous treatment. Here, KLK3 is linked to Familial prostate cancer.